Newer antithrombotic strategies in the initial management of non-ST- segment elevation acute coronary syndromes

Annals of Pharmacotherapy

Volumn 34, Issue 2, 2000, Pages 208-227

  Mathis, A Scott ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b SAINT BARNABAS MEDICAL CENTER   (United States)

Author keywords

Angina; Heparin; Low molecular weight heparin; Myocardial infarction; Platelet aggregation inhibitors; Unstable angina

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; TICLOPIDINE; TIROFIBAN;

HEART INFARCTION; HEART MUSCLE ISCHEMIA; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; UNSTABLE ANGINA PECTORIS;

EID: 0033973365     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19035     Document Type: Review

References (126)

1. White HD. Unmet therapeutic needs in the management of acute ischemia. Am J Cardiol 1997;80(suppl 4A):2B-10B.
2. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, et al. ACC/AHA Guidelines for the Management of Patients with Acute Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996;28:1328-428.
3. Braunwald E, Jones RH, Mark DB, Brown J, Brown L, Cheitlin MD, et al. Diagnosing and managing unstable angina. Circulation 1994;90:613-22.
4. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (first of two parts). N Engl J Med 1992;326:242-50.
5. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (second of two parts). N Engl J Med 1992;326:310-8.
6. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-50.
7. Kullo IJ, Edwards WD, Schwartz RS. Vulnerable plaque: pathobiology and clinical implications. Ann Intern Med 1998;129:1050-60.
8. DeWood MA, Stifter WF, Simpson CS, Spores J, Eugster GS, Judge TP, et al. Coronary arteriographic findings soon after non-Q-wave myocardial infarction. N Engl J Med 1986;315:417-23.
9. Ferguson JJ. Conventional antithrombotic approaches. Am Heart J 1995; 130:651-7.
10. Cairns JA, Théroux P, Lewis HD, Ezekowitz M, Meade TW, Sutton GC. Antithrombotic agents in coronary artery disease. Chest 1998;114(suppl): 611S-33S.
11. Frishman WH, Burns B, Atac B, Alturk N, Altajar B, Lerrick K. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am Heart J 1995;130:877-92.
12. LeBreton H, Plow EF, Topol EJ. Role of platelets after percutaneous coronary revascularization. J Am Coll Cardiol 1996;28:1643-51.
13. Weitz JI, Hirsh J. New antithrombotic agents. Chest 1998;114(suppl): 715S-727S.
14. Dobesh PP, Latham KA. Advancing the battle against acute ischemic syndromes: a focus on the GP IIb-IIIa inhibitors. Pharmacotherapy 1998; 18:663-85.
15. Ferguson JJ, Lau TK. New antiplatelet agent for acute coronary syndromes. Am Heart J 1998;135(suppl):S194-200.
16. Zaacks SM, Liebson PR, Calvin JE, Parrillo JE, Klein LW. Unstable angina and non-Q-wave myocardial infarction: does the clinical diagnosis have therapeutic implications? J Am Coll Cardiol 1999;33:107-18.
17. Hamm CW, Ravkilde J, Gerhardt W, Jorgensen P, Peheim E, Ljungdahl L, et al. The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992;327:146-50.
18. Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz, T. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med 1997;337:1648-53.
19. Roberts R, Fromm RE. Management of acute coronary syndromes based on risk stratification by biochemical markers. An idea whose time has come. Circulation 1998;98:1831-3.
20. Geraets DR. The heart and myocardial infarction. In: Traub SL, ed. Basic skills in interpreting laboratory data. Bethesda, MD: American Society of Health-System Pharmacists, 1996:187-211.
21. Armstrong PW, Fu Y, Chang WC, Topol EJ, Granger CB, Betriu A, et al. Acute coronary syndromes in the GUSTO-IIb trial. Prognostic insights and impact of recurrent ischemia. Circulation 1998;98:1860-8.
22. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-82.
23. Savonitto S, Ardissino D, Granger CB, Morando G, Prando MD, Mafrici A, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 1999;281:707-13.
24. Cannon CP, McCabe CH, Stone PH, Rogers WJ, Schactman M, Thompson BW, et al. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q-wave myocardial infarction: results of the TIMI III registry ECG ancillary study. J Am Coll Cardiol 1997;30:133-40.
25. Braunwald E. Unstable angina. A classification. Circulation 1989;80: 410-4.
26. Braunwald E. Unstable angina. An etiologic approach to management. Circulation 1998;98:2219-22.
27. Calvin JE, Klein LW, VanderBerg BJ, Meyer P, Condon JV, Snell RJ, et al. Risk stratification in unstable angina. Prospective validation of the Braunwald classification. JAMA 1995;273:136-41.
28. Katz DA, Griffith JL, Beshansky JR, Selker HP. The use of empiric clinical data in the evaluation of practice guidelines for unstable angina. JAMA 1996;276:1568-74.
29. Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE. Adjunctive drug therapy of acute myocardial infarction - evidence from clinical trials. N Engl J Med 1996;335:1660-7.
30. Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997; 336:847-60.
31. Lewis HD, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983;309: 396-403.
32. Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, et al. Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med 1985; 313:1369-75.
33. Théroux P, Ouimet H, McCans J, Latour JG, Joly P, Lévy G, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319:1105-11.
34. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-30.
35. Nowak MM, Brundhofer B, Gibaldi M. Rectal absorption from aspirin suppositories in children and adults. Pediatrics 1974;54:23-6.
36. Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, et al. Antiplatelet treatment with ticlopidine in unstable angina. Circulation 1990;82:17-26.
37. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998;129:394-405.
38. Berger PB, Bell MR, Hasdai D, Grill DE, Melby S, Holmes DR. Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. Circulation 1999;99:248-53.
39. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
40. Pepine CJ. Aspirin and newer orally active antiplatelet agents in the treatment of the post-myocardial infarction patient. J Am Coll Cardiol 1998;32:1126-8.
41. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114(suppl):489-510.
42. Collins R, MacMahon S, Flather M, Baigent C, Remvig L, Mortensen S, et al. Clinical effects of anticoagulation therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ 1996; 313:652-9.
43. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996;276:811-5.
44. Holdright D, Patel D, Cunningham D, Thomas R, Hubbard W, Hendry G, et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol 1994;24:39-45.
45. Landolfi R, De Candia E, Rocca B, Ciabattoni G, Antinori A, Masetti R, et al. Effects of unfractionated and low molecular weight heparins on platelet thromboxane biosysthesis "in vivo." Thromb Haemost 1994;72: 942-6.
46. Théroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992; 327:141-5.
47. Granger CB, Miller JM, Bovill EG, Gruber A, Tracy RP, Krucoff MW, et al. Rebound increases in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995;91:1929-35.
48. Becker RC, Liu L, Li Y, Ball SP, Spencer FA, Burns M. Heparin weaning attenuates but does not prevent rebound thrombin generation in acute coronary syndromes: results from a randomized pilot study (abstract). J Am Coll Cardiol 1999;33(suppl A):400A.
49. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337:447-52.
50. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Circulation 1994;89: 1545-56.
51. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
52. The PRISM-PLUS Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
53. Boden WE, O'Rourke RA, Crawford MH, Blaustein AS, Deedwania PC, Zoble RG, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med 1998;338:1785-92.
54. Yusuf S, Flather M, Pogue J, Hunt D, Varigos J, Piegas L, et al. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. Lancet 1998;352:507-14.
55. Topol EJ. What role for catheter laboratories in unstable angina? Lancet 1998;352:500-1.
56. Eisenstein EL. Patient risk or physician practice: what factors drive resource utilization in unstable angina? Am Heart J 1998;136:365-7.
57. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-98.
58. Turpie AGG. Pharmacology of the low-molecular-weight heparins. Am Heart J 1998;135(suppl):S329-35.
59. Spinler SA, Nawarskas JJ. Low-molecular-weight heparins for acule coronary syndromes. Ann Pharmacother 1998;32:103-10.
60. Rodman DP. Low-molecular-weight heparins in coronary arterial thrombus disease: a review of the literature. Pharmacotherapy 1998;18:265-72.
61. Noble S, Spencer CM. Enoxaparin. A review of its clinical potential in the management of coronary artery disease. Drugs 1998;56:259-72.
62. Howard PA. Dalteparin: a low-molecular-weight heparin. Ann Pharmacother 1997;31:192-203.
63. Hirsh J. Low-molecular-weight heparin. A review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. Circulation 1998;98:1575-82.
64. Bates ER. Clinical trial results with hirudin and bivalirudin for acute coronary artery syndromes. Semin Thromb Hemost 1997;23:575-81.
65. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.
66. Kleiman NS, Lincoff AM, Ohman EM, Harrington RA. Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings. Am Heart J 1998;136(suppl):S32-42.
67. Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998;98:2829-35.
68. Tisdale JE. Antiplatelet therapy in coronary artery disease: review and update of efficacy studies. Am J Health-Syst Pharm 1998;55(suppl 1):S8-16.
69. Chong PH. Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases. Am J Health-Syst Pharm 1998;55:2363-86.
70. McClellan KJ, Goa KL. Tirofiban. A review of its use in acute coronary syndromes. Drugs 1998;56:1067-80.
71. Goa KL, Noble S. Eptifibatide. A review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs 1999;57:439-62.
72. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997;80(suppl 4A):11B-20B.
73. Faulds D, Sorkin EM. Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs 1994; 48:583-98.
74. Alexander JH, Harrington RA. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. Drugs 1998;56:965-76.
75. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999;353:227-31.
76. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable angina or postinfarction angina. N Engl J Med 1995;333:764-9.
77. Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 1999;353:429-38.
78. Cohen M. New therapies for unstable angina and non-Q-wave myocardial infarction: recent clinical trials. Am Heart J 1998;135(suppl):S343-52.
79. Sharma GVRK, Lapsley D, Vita JA, Sharma S, Coccio E, Adelman B, et al. Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris. Am J Cardiol 1993;72:1357-60.
80. Lidón RM, Théroux P, Juneau M, Adelman B, Maraganore J. Initial experience with direct antithrombin, hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects. Circulation 1993;88:1495-501.
81. Fuchs J, McCabe CH, Antman EM, Borzak S, Palisaitis D, Herson S, et al. Hirulog in the treatment of unstable angina: results of the TIMI 7 trial (abstract). J Am Coll Cardiol 1994;23(suppl A):56A.
82. Topol EJ, Fuster V, Harrington RA, Califf RM, Kleiman NS, Kereiakes DJ, et al. Recombinant hirudin for unstable angina. A multicenter, randomized trial. Circulation 1994;89:1557-66.
83. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631-7.
84. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia with ST elevation. Circulation 1997;96:769-77.
85. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinvas S. The weight-based heparin dosing nomogram compared to with a "standard care" nomogram. Ann Intern Med 1993;119:874-81.
86. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-8.
87. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AGG, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease (FRIC). Circulation 1997;96:61-8.
88. Fragmin and Fast Revascularization During Instability in Coronary Artery Disease (FRISC II) Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomized multicentre study. Lancet 1999;354:709-15.
89. Fragmin and Fast Revascularization During Instability in Coronary Artery Disease (FRISC II) Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomized multicentre study. Lancet 1999;354:701-7.
90. Kontny F. Reactivation of the coagulation system: rationale for long-term antithrombotic treatment. Am J Cardiol 1997;80(suppl A):55E-60E.
91. Mark DB, Cowper PA, Berkowitz SD, Davidson-Ray L, DeLong ER, Turpie AGG, et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome. Results from the ESSENCE trial. Circulation 1998;97:1702-7.
92. Antman EM. TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Am Heart J 1998;135(suppl):S353-60.
93. Antman EM, McCabe CH, Gurfinkel EP, Turpie AGG, Bernink PJLM, Salein D, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation 1999;100:1593-601.
94. Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602-8.
95. Krulewitz A. Low-molecular-weight heparin versus unfractionated heparin for unstable coronary disease (letter). N Engl J Med 1998;338:130.
96. Cohen M. Low-molecular-weight heparin versus unfractionated heparin for unstable coronary disease (letter). N Engl J Med 1998;338:131.
97. Bozovich GE, Gurfinkel EP, Antman EM, Colorio C, McCabe CH, Mautner B, et al. Enoxaparin is superior to unfractionated heparin regardless of aPTT range achieved: a TIMI 11B substudy (abstract). J Am Coll Cardiol 1999;33(suppl A):352A.
98. Bernick PJLM, Antman EM, McCabe CH, Horacek T, Papuchis G, Mautner B, et al. Treatment benefit is greatest in patients at highest risk: a multivariate analysis from TIMI 11B (abstract). J Am Coll Cardiol 1999;33(suppl A):352A.
99. Lopez-Sendon J, Antman EM, McCabe CH, Gurfinkel E, Turpie AG, Fox KM, et al. Superiority of enoxaparin over unfractionated heparin in unstable angina occurs early in treatment: results from TIMI 11B (abstract). J Am Coll Cardiol 1999;33(suppl A):352A.
100. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin in unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997;29:1474-82.
101. Topol EJ. The future of antithrombotic and antiplatelet therapy for ischemic heart disease. Am Heart J 1998;136(suppl):S66-8.
102. Deutsch E, Cohen M, Radley DR, Tarazona N, Fromell GJ. Safety and efficacy of percutaneous procedures in patients receiving subcutaneous enoxaparin for unstable angina: results of the ESSENCE trial (abstract). Circulation 1998;98(suppl I):I-563.
103. Madan M, Berkowitz SD, Tcheng JE. Glycoprotein IIb/IIIa integrin blockade. Circulation 1998;98:2629-35.
104. Simoons ML, Jan de Boer M, van den Brand MJBM, van Miltenburg AJM, Hoorntje JCA, Heyndrickx GR, et al. Randomized trial of a GP IIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994;89:596-603.
105. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
106. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-6.
107. 3 blockade with percutaneous coronary intervention. JAMA 1997;278:479-84.
108. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
109. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
110. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
111. Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1997;30:149-56.
112. Patrono C, Coller B, Dalen JE, Fuster V, Gent M, Harker LA, et al. Platelet-active drugs. The relationship among dose, effectiveness, and side effects. Chest 1998;114(suppl):470S-88S.
113. Mark DB, Talley D, Topol EJ, Bowman L, Lam LC, Anderson KM, et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. Circulation 1996;94:629-35.
114. van Hout BA, Bowman L, Zellinger DJ, Simoons ML. Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Am Heart J 1998;135(suppl):S98-106.
115. Pepine CJ, Holmes DR. Coronary artery stents. J Am Coll Cardiol 1996;28:782-94.
116. Topol EJ, Serruys PW. Frontiers in interventional cardiology. Circulation 1998;98:1802-20.
117. Klootwijk P, Meij S, Melkert R, Lenderink T, Simoons ML. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE). Circulation 1998;98:1358-64.
118. Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999;340: 1623-9.
119. Harrington RA, Kleiman NS, Granger CB, Ohman EM, Berkowitz SD. Relation between inhibition of platelet aggregation and clinical outcomes. Am Heart J 1998;136(suppl):S43-50.
120. Chandra NC, Ziegelstein RC, Rogers WJ, Tienfenbrunn AJ, Gore JM, French WJ, et al. Observations of the treatment of women in the United States with myocardial infarction. Arch Intern Med 1998;158:981-8.
121. The PRISM Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-505.
122. Akkerhuis M, Boersma E, Harrington RA, Deckers JW, Califf RM, Simoons ML. Eptifibatide protects against adverse cardiac complications both before and during percutaneous intervention in patients with acute coronary syndromes without ST-elevation (abstract). J Am Coll Cardiol 1999;33(suppl A):40A.
123. Package insert. Integrilin (eptifibatide). Kenilworth, NJ: Key Pharmaceuticals, May 1998.
124. Package insert. Aggrastat (tirofiban). West Point, PA: Merck and Co., Inc., May 1998.
125. Cannon CP, Weintraub WS, Demopoulos LA, Robertson DH, Gormley GJ, Braunwald E. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 trial. Am J Cardiol 1998;82:731-6.
126. Weintraub WS, Culler SD, Kosinski A, Becker ER, Mahoney E, Burnette J, et al. Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (treat angina with Aggrastat [tirofiban] and determine cost of therapy with invasive or conservative strategy) - TIMI 18 trial. Am J Cardiol 1999;83:317-22.